Figure 8.
Effect of GSK2795039 on superoxide production in PAG, PMC, and aorta. GSK2795039 significantly reduced NADPH-dependent superoxide production in PAG and PMC, comparable to that in the aorta. Note: the level of superoxide without the inhibitor in each tissue was taken as 100%. * p < 0.05 vs. control, PAG, n = 10; PMC, n = 6; ** p < 0.01 vs. control, aorta, n = 6. GSK2795039 concentration: 25 μM.